News for RemeGen Co., Ltd. (9995.HK)

YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC) in an oral presentation. This marks the first public disclosure of results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy as a perioperative therapy for MIBC. The pathological complete response (pCR) rate reached an impressive 63.6%, which is a breakthrough improvement compared with traditional neoadjuvant chemotherapies (36%-42%). ASCO GU is one of the top urologic oncology conferences that leading experts worldwide in this field attend.

Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

PR NewswireYANTAI, China, Dec. 12, 2024 YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight S

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ('RemeGen' or 'the Company') (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially accepted by the Center for Drug Evaluation (CDE) of the China National Food and Drug Administration and has been included in the priority review and approval process.

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ('RemeGen' or 'the Company') (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept has achieved the first patient enrollment in the United States for its global multi-center phase III clinical trial for the treatment of generalized myasthenia gravis (gMG).

First patient enrollment in the U.S. - A milestone for the global multi-center phase …¢ clinical trial of telitacicept for myasthenia gravis

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021. The financing was led by Lapam Capital with strong support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the Charcot-Marie Tooth Research Foundation (CMTRF).

The S1PR modulators market is expected to show a remarkable expansion, driven by advancements in pharmaceutical research and therapeutic applications. With...

Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously un…

Bladder cancer, marked by abnormal cell growth in the bladder lining, presents a global health concern. The incidence of bladder cancer is on the rise due...

/PRNewswire/ -- DelveInsight's Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...

/PRNewswire/ -- DelveInsight's Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...

/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...

/PRNewswire/ -- DelveInsight's 'Pancreatic Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

/PRNewswire/ -- DelveInsight's 'Gastric Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

As per DelveInsight Multiple Sclerosis pipeline involves 100+ key companies developing 100+ Multiple Sclerosis treatment therapies...

Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as...